Proceedings of the 1st Tarumanagara International Conference on Medicine and Health (TICMIH 2021)

Severe COVID-19 Treatment Using Hypoxic-Mesenchymal Stem Cell Secretome: A Case Report

Authors
Siufui Hendrawan1, 2, *, Sandy Qlintang3, Ronald Winardi Kartika4, Vera Kurniawati5, David Victorious Lukas6
1Department of Biochemical and Molecular Biology, Faculty of Medicine, Tarumanagara University, Jakarta
2Tarumanagara Human Cell Technology Laboratory, Jakarta
3Stem Cell and Cancer Institute Kalbe, Jakarta
4Faculty of Medicine, Krida Wacana Christian University, Jakarta
5Faculty of Medicine, Pelita Harapan University, Tangerang
6Director of Marketing, P.T. Ananta Karya Sejahtera, Tangerang
*Corresponding author. Email: siufui@fk.untar.ac.id
Corresponding Author
Siufui Hendrawan
Available Online 1 December 2021.
DOI
https://doi.org/10.2991/ahsr.k.211130.049How to use a DOI?
Keywords
Covid-19; Cytokine storm; Secretome-Mesenchymal Stem Cell
Abstract

COVID-19 (SARS COV-2) has a serious adverse effect in the form of Acute Respiratory Distress Syndrome (ARDS) caused by a hyper-inflammation event (‘cytokine storm’) that causes damage to the lung tissue. Previous studies have shown a link between disease severity and excessive elevation of pro-inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-α) and interleukin 6 (IL-6). This discovery is substantiated by the plasma cytokine levels found in the majority of patients suffering from severe COVID-19 with extensive lung damage.

Recently, mesenchymal stem cells (MSCs) have shown their potency in combating the cytokine storm due to their immune-modulatory, anti-inflammation, and paracrine effects. MSCs cultured under hypoxic conditions may increase the activity of solutes known as Secretome-MSCs (S-MSCs), such as interleukin 10 (IL-10), and transforming growth factor beta (TGF-β), which are considered as principal contributing factors in reducing inflammation. In addition, they can also increase the expression of growth factors such as vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF) that accelerate the repair of the lung injury.

In this case report, we report an effective therapy to control the COVID-19 cytokine storm that regenerates damaged lungs. A severely ill COVID-19 patient with comorbidities suffered ARDS. Standard therapy was given with no improvement. Secretome-MSCs administration was suggested. A total of 7 vials were injected in the patient via an intramuscular route. Two weeks after the last dose was administered, the patient’s condition significantly improved.

Current clinical findings show the curative prospect of secretome-MSC in the therapy of COVID-19 related ARDS.

Copyright
© 2021 The Authors. Published by Atlantis Press International B.V.
Open Access
This is an open access article under the CC BY-NC license.

Download article (PDF)

Volume Title
Proceedings of the 1st Tarumanagara International Conference on Medicine and Health (TICMIH 2021)
Series
Advances in Health Sciences Research
Publication Date
1 December 2021
ISBN
978-94-6239-473-5
ISSN
2468-5739
DOI
https://doi.org/10.2991/ahsr.k.211130.049How to use a DOI?
Copyright
© 2021 The Authors. Published by Atlantis Press International B.V.
Open Access
This is an open access article under the CC BY-NC license.

Cite this article

TY  - CONF
AU  - Siufui Hendrawan
AU  - Sandy Qlintang
AU  - Ronald Winardi Kartika
AU  - Vera Kurniawati
AU  - David Victorious Lukas
PY  - 2021
DA  - 2021/12/01
TI  - Severe COVID-19 Treatment Using Hypoxic-Mesenchymal Stem Cell Secretome: A Case Report
BT  - Proceedings of the 1st Tarumanagara International Conference on Medicine and Health (TICMIH 2021)
PB  - Atlantis Press
SP  - 290
EP  - 295
SN  - 2468-5739
UR  - https://doi.org/10.2991/ahsr.k.211130.049
DO  - https://doi.org/10.2991/ahsr.k.211130.049
ID  - Hendrawan2021
ER  -